This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

Cellomatics moves to new HQ after surge in demand for discovery services

Share this article

UK CRO Cellomatics Biosciences has moved to a purpose built headquarter in Nottingham, citing growing demand for preclinical and early drug discovery services.

The new facility – which is roughly three times the size of the contract research organization’s (CRO) previous base in the city – houses laboratories kitted out with imagining and analytical technologies as well as office space and meeting rooms.

The firm – which was founded in 2015 – also revealed it has doubled its revenue over the past three years and this growth – combined with the resurgent research market - prompted the relocation says CEO and founder, Shailendra Singh.

“Drug development is a truly global market and the number of biotechs, pharma companies and academic groups working on the translation of ideas into medicines continues to increase, and as does the funding available to support such projects.

“The changing dynamic of the industry means that companies are increasingly looking to specialist CROs for the expertise they need,” Singh continued, adding “We are delighted to be expanding our footprint in Nottingham.

“Our new state-of-the-art facilities provide a collaborative working environment for our valued workforce, and will enable us to accelerate our plans for further recruitment and to attract the very best scientists to Cellomatics.”

Strategic investors

Finance director Stuart Gibson put the move in context of the firm’s wider growth plan, which will include deals with investors.

“Cellomatics is well-positioned to double top-line organic revenue over the next two years through expansion into new markets, focusing on new therapeutic areas, developing or acquiring new technologies, and building new service offerings.

“We also plan to partner with strategic investors to further accelerate our growth. As a company, we are committed to developing additional capabilities to enhance the depth of our services within our current specialist sectors, and to expand into other growing sectors.”

Image: Stock Photo Secrets

Share this article

Sign up for Clinical Insider email updates